Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults

In a placebo-controlled, phase 2–3 trial, one dose of mRNA-1345 led to a lower incidence of RSV disease among adults 60 years of age or older. Solicited local and systemic adverse reactions occurred more often with the vaccine.

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 389; číslo 24; s. 2233 - 2244
Hlavní autori:	Wilson, Eleanor, Goswami, Jaya, Baqui, Abdullah H., Doreski, Pablo A., Perez-Marc, Gonzalo, Zaman, Khalequ, Monroy, Jorge, Duncan, Christopher J.A., Ujiie, Mugen, Rämet, Mika, Pérez-Breva, Lina, Falsey, Ann R., Walsh, Edward E., Dhar, Rakesh, Wilson, Lauren, Du, Jiejun, Ghaswalla, Parinaz, Kapoor, Archana, Lan, Lan, Mehta, Shraddha, Mithani, Runa, Panozzo, Catherine A., Simorellis, Alana K., Kuter, Barbara J., Schödel, Florian, Huang, Wenmei, Reuter, Caroline, Slobod, Karen, Stoszek, Sonia K., Shaw, Christine A., Miller, Jacqueline M., Das, Rituparna, Chen, Grace L.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 14.12.2023
Predmet:	Aged Aging Aging General Antibodies, Viral Chronic obstructive pulmonary disease Clinical Medicine Clinical Medicine General Clinical trials Confidence intervals Critical Care Critical Care General Double-Blind Method Geriatrics Glycoproteins Humans Infections Infectious Disease Infectious Disease General Middle Aged Morbidity mRNA mRNA Vaccines - adverse effects mRNA Vaccines - therapeutic use Older people Outpatient-Based Clinical Medicine Placebos Product development Pulmonary Respiratory diseases Respiratory syncytial virus Respiratory Syncytial Virus Infections - epidemiology Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus Vaccines - adverse effects Respiratory Syncytial Virus Vaccines - therapeutic use Respiratory Syncytial Virus, Human - genetics Respiratory tract diseases Respiratory Tract Diseases - diagnosis Respiratory Tract Diseases - epidemiology Respiratory Tract Diseases - prevention & control Safety Side effects Statistical analysis Success Treatment Outcome Vaccine efficacy Vaccines Viral Infections
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	In a placebo-controlled, phase 2–3 trial, one dose of mRNA-1345 led to a lower incidence of RSV disease among adults 60 years of age or older. Solicited local and systemic adverse reactions occurred more often with the vaccine.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2307079